Yao‐Yu Hsieh

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Pei‐Ming Yang · 3 shared papers, 2019–2022 · strength 0.56
   • Paper Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Panc… DOI 10.3390/ijms23126559↗
   • Paper Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Ade… DOI 10.3390/jpm10030130↗
   • Paper Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in … DOI 10.3390/genes10100766↗
2. Ching‐Chung Ko · 1 shared paper, 2022 · strength 0.26
   • Paper Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Panc… DOI 10.3390/ijms23126559↗
3. Nai‐Jung Chiang · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
4. Jen‐Shi Chen · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
5. Kun‐Ming Rau · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
6. Yung‐Yeh Su · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
7. Li‐Tzong Chen · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
8. Tai‐Jan Chiu · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
9. I‐Wei Ho · 1 shared paper, 2026 · strength 0.25
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
10. Li‐Yuan Bai · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
11. Chung‐Pin Li · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
12. Yan‐Shen Shan · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
13. Li-Wei Liu · 1 shared paper, 2020 · strength 0.19
    • Paper Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Ade… DOI 10.3390/jpm10030130↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.